{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:03:41Z","timestamp":1790233421829,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Intravenous tocilizumab is currently dosed on body weight, although a weak correlation between body weight and clearance has been described. The aim of the study was to assess the current dosing strategy and provide a scientific rational for dosing using a modelling and simulation approach.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Serum concentrations and covariates were obtained from intravenous tocilizumab treated subjects at a dose of 4, 6 or 8\u00a0mg every 28\u00a0days. A population pharmacokinetic analysis was performed using nonlinear mixed effects modelling. The final model was used to simulate tocilizumab exposure to assess a dosing strategy based on body weight or fixed dosing, using as target a cumulative area under the curve at 24\u00a0weeks of treatment above 100 \u00d7 10<jats:sup>3<\/jats:sup>\u00a0\u03bcg\u00a0h\u00a0ml<jats:sup>\u20131<\/jats:sup>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A one\u2010compartment disposition model with parallel linear and nonlinear elimination best described the concentration\u2013time data. The typical population mean values for clearance, apparent volume of distribution, maximum elimination rate and Michaelis\u2013Menten constant were 0.0104\u00a0l\u00a0h<jats:sup>\u20131<\/jats:sup>, 4.83\u00a0l, 0.239\u00a0mg\u00a0h<jats:sup>\u20131<\/jats:sup> and 4.22\u00a0\u03bcg\u00a0ml<jats:sup>\u20131<\/jats:sup>, respectively. Interindividual variability was included for clearance (17.0%) and volume of distribution (30.8%). Significant covariates for clearance were patient body weight and C\u2010reactive protein serum levels. An estimated exponent for body weight of 0.360 confirms the weak relationship with tocilizumab clearance. Simulations demonstrate that patients with lower weights are at risk of underdosing if the weight\u2010based dosing approach is used. However, fixed\u2010dosing provides a more consistent drug exposure regardless of weight category.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our study provides evidence to support fixed dosing of intravenous tocilizumab in rheumatoid arthritis patients since it reduces variability in tocilizumab exposure among weight categories compared to the current weight\u2010based dosing approach.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13500","type":"journal-article","created":{"date-parts":[[2018,1,9]],"date-time":"2018-01-09T18:52:24Z","timestamp":1515523944000},"page":"716-725","source":"Crossref","is-referenced-by-count":22,"title":["Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0845-8107","authenticated-orcid":false,"given":"Carla","family":"Bastida","sequence":"first","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic Barcelona Universitat de Barcelona  Spain"},{"name":"Department of Pharmacy &amp; Pharmacology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ruiz\u2010Esquide","sequence":"additional","affiliation":[{"name":"Arthritis Unit, Rheumatology Department, Hospital Clinic Barcelona Universitat de Barcelona  Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariona","family":"Pascal","sequence":"additional","affiliation":[{"name":"Immunology Department, CDB, Hospital Clinic Barcelona Universitat de Barcelona  Spain"},{"name":"IDIBAPS  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia H. M.","family":"de Vries Schultink","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Yag\u00fce","sequence":"additional","affiliation":[{"name":"Immunology Department, CDB, Hospital Clinic Barcelona Universitat de Barcelona  Spain"},{"name":"IDIBAPS  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raimon","family":"Sanmart\u00ed","sequence":"additional","affiliation":[{"name":"Arthritis Unit, Rheumatology Department, Hospital Clinic Barcelona Universitat de Barcelona  Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology The Netherlands Cancer Institute\u2010Antoni van Leeuwenhoek  Amsterdam The Netherlands"},{"name":"Department of Clinical Pharmacy University Medical Center Utrecht, Utrecht University  Utrecht The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Soy","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Division of Medicines, Hospital Clinic Barcelona Universitat de Barcelona  Spain"},{"name":"IDIBAPS  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13192"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150310141827"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0296-9"},{"key":"e_1_2_9_5_1","first-page":"349","article-title":"Tocilizumab in the treatment of rheumatoid arthritis and beyond","volume":"8","author":"Shetty A","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_9_6_1","unstructured":"RoActemra\u00ae SPC (Roche registration Limited) 2009. [Internet]. [cited 2017 Mar 15]. Available from:http:\/\/www.ema.europa.eu\/docs\/es_ES\/document_library\/EPAR_\u2010_Product_Information\/human\/000955\/WC500054890.pdf"},{"key":"e_1_2_9_7_1","unstructured":"Actemra\u00ae SPC (Genentech Inc.) 2010. [Internet]. [cited 2017 Jan 25]. Available from:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125276s092lbl.pdf"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2013.04.012"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu461"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60453-5"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012437585"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009350623"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_9_17_1","unstructured":"BealS SheinerL BoeckmannA BauerR.NONMEM User's Guides. (1989\u20132009). v. 7.3. Icon Dev. Solut. Ellicott City MD USA 2009."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2010.04.018"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01113502"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1016215116835"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9361-x"},{"key":"e_1_2_9_22_1","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2016"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-2607(98)00067-4"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2003.11.003"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-009-9133-0"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsb.2006.10.003"},{"key":"e_1_2_9_28_1","doi-asserted-by":"crossref","unstructured":"HardingSD SharmanJL FaccendaE SouthanC PawsonAJ IrelandS et al.The IUPHAR\/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. Nucl Acids Res2018;45:D1091\u2013D1106.","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13876"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000389"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2014.926219"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev279"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.48.113006.094708"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337512"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02622.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13500","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13500","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:13:34Z","timestamp":1695568414000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1111\/bcp.13500"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13500","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}